Download Free Medical The Impact of COVID-19 on Cancer Treatment

The Impact of COVID-19 on Cancer Treatment - EU5 Report PowerPoint Presentation

DOWNLOAD MEDICAL POWERPOINT PRESENTATION

About This Presentation

Description : This report titled, “The Impact of COVID-19 on Cancer Treatment - EU5 Report” is by the IQVIA Institute and is a voluntary, unpaid, IQVIA-sponsored survey of Oncologists, Hem-oncologists and Onco-surgeons examining the impact of coronavirus COVID-19 on cancer treatment in EU5.

Tags : Healthcare, Oncology, cancer, Cancer Treatment, COVID-19, EU5, Oncologists, Hem-oncologists, Onco-surgeons

Published on : Jul 20, 2020 | Views : 1556 | Downloads : 0

Shareable Url :

Embed Code :

Comment

Transcript

Slide 1-

© 2020. All rights reserved. IQVIA® is a registered trademark of IQVIA Inc. in the United States, the European Union, and various other countries. EU 5 Report Impact of COVID-19 on Cancer Treatment Natalie Harb - Senior Principal Global Consulting and Analytics Solutions
Slide 2-

1 Overview What is the purpose of this report? The purpose of this report is to determine if there has been any changes reported in the treatment of cancer across the EU 5 countries now as countries ease restrictions and exit lockdown. We will be comparing what Onco Specialists are telling us now (Wave 2) vs what they said at the start of the pandemic (Wave 1) The information gathered from IQVIA’s Onco Specialists community provides insight and understanding into key topics such as: The impact of cancer patient visits at different phases during COVID -19 Interaction via telehealth/ remote consultations during difference phases of the pandemic What specific type of treatment practices are impacted? What are the current changes anticipated now that restrictions are being relaxed? What pharma/biotech initiatives can help Onco Specialists deliver the best care possible their patients? What communication channels are pharma companies using to communicate with Onco Specialists? How and When was the data collected? Onco Specialists were invited to participate via email and the survey was hosted on DocNet – IQVIA’s internal and secure online community for healthcare professionals This survey was not sponsored by any IQVIA client/customer. IQVIA was not compensated in any way for this survey Data collection occured from the 17th of June – 22nd of June 2020 (Wave 2) We will be comparing results with our Wave 1 survey that took place between 2nd of April – 8th of April 2020 (Wave 1) Impact of COVID-19 on cancer treatment – EU5 June 2020. Copyright 2020 IQVIA. All rights reserved.
Slide 3-

Across the EU5, 383 Onco Specialists voluntarily participated in a 3 mins survey that IQVIA hosted on DOCNET 30% Hematologist 17% Hem-Oncologist 49% Oncologists 2% Onco-surgeon 1% Radiotherapists 1% Others* Wave 2 (n=383) Impact of COVID-19 on cancer treatment – EU5 June 2020. Copyright 2020 IQVIA. All rights reserved. 2 Sample split *Others include pulmonologists, respiratory physicians treating cancer etc. Q0. Which of the following best describes your primary medical specialty?
Slide 4-

52% 43% 54% 57% 48% 66% 36% 28% 36% 40% 36% 38% Percentage caseload dip from Pre-COVID phase Wave 1 Wave 2 Q1: After the COVID-19 outbreak, are you seeing fewer hematology/oncology patients per week? EU5 DE FR Impact of COVID-19 on cancer treatment – EU5 June 2020. Copyright 2020 IQVIA. All rights reserved. 3 IT ES UK n=189 n=226 n=26 n=20 n=31 n=39 n=57 n=71 n=52 n=58 n=23 n=38 An overall improvement in patient visit rates due to the easing of restrictions: Onco specialists now see only 36% fewer patients per week vs 52% in April
Slide 5-

However, the average count of cancer patients seen post COVID-19 outbreak is still far-off from pre COVID-19 days Average* number of cancer patients seen prior to COVID-19 outbreak Average number of cancer patients seen per week (Wave 1) Average number of cancer patients seen last week (Wave 2) 81 Patients 41 Patients 50 Patients Pandemic Outburst Exiting Lockdown Wave 2 (n=226) * Weighted average of Wave 1 and Wave 2 Note: All numbers shown in slide are absolute numbers (number of patients) Q1: After the COVID-19 outbreak, are you seeing fewer hematology/oncology patients per week? Impact of COVID-19 on cancer treatment – EU5 June 2020. Copyright 2020 IQVIA. All rights reserved. 4 Wave 1 (n=189) Number of cancer patients seen during COVID 19 outbreak
Slide 6-

Number of cancer patients seen during COVID 19 outbreak – individual country breakdown This is particularly true for France where the average number of patients seen has not increased whereas Germany is seeing a fast recovery to pre-COVID * Weighted average of Wave 1 and Wave 2 Note: All numbers shown in slide are absolute numbers (number of patients) Q1: After the COVID-19 outbreak, are you seeing fewer hematology/oncology patients per week? Impact of COVID-19 on cancer treatment – EU5 June 2020. Copyright 2020 IQVIA. All rights reserved. 5 levels
Slide 7-

Restrictions led to a huge spike in remote consultations (6% to 56%), however with time, Onco Specialists believe this would become a part of their practice 6% Prior to COVID outbreak 56% During lockdown 34% Post lockdown 19% When COVID won’t exist % proportion of patients on remote consultations Q2: Could you please estimate the typical proportion of interaction via telehealth/remote consultation in the following time period? Impact of COVID-19 on cancer treatment – EU5 June 2020. Copyright 2020 IQVIA. All rights reserved. 6
Slide 8-

This is particularly true for the UK where Onco Specialists see remote consultations becoming part of their practice to a higher extent than other countries % proportion of patients on remote consultations - individual country breakdown Q2: Could you please estimate the typical proportion of interaction via telehealth/remote consultation in the following time period? Impact of COVID-19 on cancer treatment – EU5 June 2020. Copyright 2020 IQVIA. All rights reserved. 7
Slide 9-

A slight improvement vs wave 1 on delay in surgeries, less patient referrals and low number of biopsies even though these are still the most cited aspects of COVID-19 on cancer treatment Wave 1 Wave 2 Delay in surgeries 72% 51% 60% 66% 48% 47% Less number of referrals to hematologists/ oncologists Less number of biopsy/ diagnosis Wave 1 (n=221) Wave 2 (n=383) Q3: What according to you is the impact on cancer treatment practice amidst the COVID-19 crisis? Impact of COVID-19 on cancer treatment – EU5 June 2020. Copyright 2020 IQVIA. All rights reserved. 8 Impact of COVID 19 crisis on cancer treatment
Slide 10-

12% Patients Onco Specialists Hospitals Increased remote consultations, limited visitor policies and change in treatment schedule to include orals/SC therapies are some of the key practice changes seen by Onco Specialists Change in treatment protocol to introduce oral cancer medications Change treatments to include cancer medications which patients can self- administer Addition of more surgery days/ chemo cycles Increased daily working hours Increased frequency of remote consultations Refer patients to other facilities due to lack of hospital infrastructure Allow in-person visits primarily for critical and/or newly diagnosed cancer patients 39% 25% 28% 30% 79% Limited visitor policy except in case of end of life circumstances 59% 48% Q4: What key changes are you currently seeing in your practice setting as we see restrictions being relaxed to some extent now? Impact of COVID-19 on cancer treatment – EU5 June 2020. Copyright 2020 IQVIA. All rights reserved. 9
Slide 11-

Looking deeper at the changes impacting Patients, we see that in the UK 60% Onco Specialists are introducing more oral medications Change in treatment protocol to introduce oral cancer medications 39% Patients 22% 40% 28% 42% 61% Key changes observed in treatment protocol for patients - individual country breakdown 25% 22% 10% 24% 25% 47% Change treatments to include cancer medications which patients can self- administer EU5 Q4: What key changes are you currently seeing in your practice setting as we see restrictions being relaxed to some extent now? Impact of COVID-19 on cancer treatment – EU5 10
Slide 12-

Webinars 65% To maintain social distancing, E-mails, webinars and virtual meetings have become current new modes to connect with Onco Specialists Current modes of communication Expectations from pharma companies Q5: What initiatives can pharma/biotech take in order to help you manage increased cancer patients in the coming few months? Q6: In the current COVID-19 scenario, which of the following communication channels are pharma companies using to communicate with you? E-mail 84% Virtual Meetings 56% Messaging app 39% Face to face 10% Post / Direct Mail 21% Phone Call 53% No Contacts 4% To increase patient support services 73% 57% Update on the availability of critical oncology drugs for their patients Tips on how to best communicate remotely with the rest of their practice and patients 54% Availability of an online resource center which can be accessed for product related information 49% Impact of COVID-19 on cancer treatment – EU5 June 2020. Copyright 2020 IQVIA. All rights reserved. 11
Slide 13-

What are the potential implications of these findings for oncology companies? COVID-19 impact on cancer care Implications for oncology companies Reduced visits creates patient backlog Understand physician workload dealing with backlogged patients and consequent less time per patient (and to engage with pharma)- address how your company can support physicians now Delays diagnosis, treatment start, switch and type Research and quantify backlog impact on patient treatment and brand use – feed into revisions of forecasts and identify routes to improve path to treatment, including how to support home/self treatment Understand how physician/patient interactions are changing and how as a company you can support Ensure you have researched and acted on changed physician engagement preferences with your company Alters ways physicians prefer to treat and interact Impact of COVID-19 on cancer treatment – EU5 June 2020. Copyright 2020 IQVIA. All rights reserved. 12
Slide 14-

13 DISCLAIMER The start date and the ease of restrictions date of COVID-19 in each country mentioned in this report varies. This could lead to some of the differences seen at country level. In addition, some Oncology specialists might be responding to questions based on what they have actually experienced, whilst others may be based on what they believe might happen. Sample sizes are not representative at country level. In addition, the sample composition is quite different at the country level. This could lead to some of the difference noted at country level. Sample sizes both at a total EU 5 level as well as individual country level are different between Wave 1 and Wave 2 – its important to keep that in mind when making comparisons between the changes observed in responses. This was a pulse survey. The questions asked are intended to provide top level insight into what Oncology specialists across the EU5 are experiencing. Impact of COVID-19 on cancer treatment – EU5 June 2020. Copyright 2020 IQVIA. All rights reserved.
Slide 15-

© 2020. All rights reserved. IQVIA® is a registered trademark of IQVIA Inc. in the United States, the European Union, and various other countries. For further information, please contact: GlobalPI@IQVIA.com

User Presentation
Related Presentations

Get the insurance companies out of my healthcare

By: docshare
Views: 1307

Global Oncology Trends 2019 - Therapeutics, Clinical Development and Health System Implications

By: docshare
Views: 1527

Orphan Drugs in the United States - Exclusivity, Pricing and Treated Populations

By: docshare
Views: 1233

Innovation in Diabetes Care Technology

By: docshare
Views: 1362

Wellness for Everyone

By: docshare
Views: 1346

NON-HODGKIN LYMPHOMA (NHL)

By: jefer17
Views: 6375

Management of Metastatic Disease

By: VineetaBose
Views: 339

Screening for Breast Cervical Prostate and Lung Cancer

By: JenniferDwayne
Views: 1638

Salivary Gland Tumors

By: JenniferDwayne
Views: 3219

Gestational Trophoblastic Disease (GTD)

By: drdwayn
Views: 1712

docshare

About : I am a passionate medical marketing professional with hands on experience in healthcare digital marketing.
Occupation : Medical Professional
Specialty : Other Health Professionals
Country : India
Website :

HEALTH A TO Z